Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
|
|
|
|
|
|
Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
|
|
|
|
|
|
Describe case scenarios in which maintenance therapy may become standard in the near future
|
|
|
|
|
|
Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse
|
|
|
|
|
|